Cian Healthcare Ltd

Cian Healthcare Ltd has announced a revision in its market lot size for equity shares, as approved by BSE Limited. Effective August 24, 2026, the market lot has been reduced from 2,000 shares to 137 shares. This change is in accordance with the Resolution Plan approved by the Hon'ble National Company Law Tribunal (NCLT) on December 18, 2025, and follows the trading approval granted by BSE. The company is complying with SEBI regulations and the NCLT order for this adjustment.

Cian Healthcare Limited's board approved audited standalone and consolidated financial results for the year ended March 31, 2026, during its meeting on May 30, 2026. The meeting, which commenced at 02:00 P.M. and concluded at 03:35 P.M. (1ST), also addressed the audit report with modified opinions. The company is under a resolution plan approved by NCLT, with management vested in a Resolution Plan Implementation Committee.

Cian Healthcare Limited announced the audited standalone and consolidated financial results for the half-year and financial year ended March 31, 2026. The Board of Directors approved the financial results at their meeting held on May 30, 2026. The meeting also noted the audit report with modified opinion issued by M/s S SR CA & Co., Chartered Accountants. The company is undergoing a Corporate Insolvency Resolution Process (CIRP) which was restored effective August 14, 2024. A resolution plan was approved by NCLT on December 18, 2025, for ₹37,30,13,553.

Cian Healthcare Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results (standalone and consolidated) for the half year and financial year ended March 31, 2026. The trading window for dealing in the company's securities is closed for designated persons and their immediate relatives from April 1, 2026, and will remain closed until 48 hours after the declaration of the audited financial results.

Cian Healthcare Ltd has received trading approval for 2,50,00,000 (Two Crores Fifty Lakhs) fully paid-up equity shares from the Bombay Stock Exchange (BSE). The approval is for 12,50,000 (Twelve Lakhs Fifty Thousand) equity shares for public shareholders and 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) equity shares for promoters. The shares are allotted in accordance with the provisions of the NCLT Order read with the Resolution Plan approved therein.

Cian Healthcare Ltd has announced the closure of the trading window for its designated persons and their immediate relatives. The closure will be in effect from Wednesday, April 01, 2026, until 48 hours after the declaration of the Annual Audited Financial Results for the Financial Year ending March 31, 2026. The exact date of the Board of Directors' meeting for the financial results declaration will be intimated later. This decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations and the Prohibition of Insider Trading Code of Cian Healthcare Limited.

Cian Healthcare Ltd has received listing approval for 2,37,50,000 fully paid-up equity shares at a face value of INR 10/- each, amounting to INR 23,75,00,000, to the promoters on a preferential basis. The shares will be issued to Ananta Medicare Limited (55%), Rajesh Jain (21%), and Pradeep Kumar Jain (19%). The company will comply with the necessary trading formalities and credit the shares to the respective demat accounts of the shareholders. The listing approval was granted by BSE, subject to the company's compliance with Regulation 167 of SEBI (ICDR) Regulations and other applicable regulations.

Ananta Medicare Limited has acquired 1,37,50,000 equity shares of Cian Healthcare Limited at a face value of INR 10/- each, amounting to INR 13,75,00,000. This acquisition was made via allotment in the Board Meeting dated March 16, 2026, and is pursuant to the provisions of the Resolution Plan approved by the Hon'ble National Company Law Tribunal (NCLT) on December 18, 2025. The acquisition falls under the exemption provided in Regulation 10(1)(da) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pursuant to the Resolution Plan approved by the NCLT, Rajesh Jain has acquired 52.5 Lakh shares of Cian Healthcare Ltd via allotment in the Board Meeting dated March 16, 2026. The acquisition, amounting to INR 5.25 Crores, falls under the exemption provided in Regulation 10(1)(da) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pradeep Kumar Jain has acquired 47,50,000 fully paid-up equity shares of Cian Healthcare Ltd, amounting to INR 4,75,00,000, via allotment in the Board Meeting dated March 16, 2026. This acquisition is pursuant to the resolution plan approved by the Hon'ble National Company Law Tribunal, Mumbai Bench. The acquisition falls under the exemption provided in Regulation 10(1)(da) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.